Abstract
Get full access to this article
View all access options for this article.
References
1.
Rizvi
NA
,
Mazières
J
,
Planchard
D
,
Stinchcombe
TE
,
Dy
GK
,
Antonia
SJ
,
Horn
L
,
Lena
H
,
Minenza
E
,
Mennecier
B
,
Otterson
GA
,
Campos
LT
,
Gandara
DR
,
Levy
BP
,
Nair
SG
,
Zalcman
G
,
Wolf
J
,
Souquet
P-J
,
Baldini
E
,
Cappuzzo
F
,
Chouaid
C
,
Dowlati
A
,
Sanborn
R
,
Lopez-Chavez
A
,
Grohe
C
,
Huber
RM
,
Harbison
CT
,
Baudelet
C
,
Lestini
BJ
,
Ramalingam
SS
. 2015 . Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial . Lancet Oncol , 16 :257 –265 .
2.
Sharma
P
,
Retz
M
,
Siefker-Radtke
A
,
Baron
A
,
Necchi
A
,
Bedke
J
,
Plimack
ER
,
Vaena
D
,
Grimm
M-O
,
Bracarda
S
,
Arranz
JÁ
,
Pal
S
,
Ohyama
C
,
Saci
A
,
Qu
X
,
Lambert
A
,
Krishnan
S
,
Azrilevich
A
,
Galsky
MD
. 2017 . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial . Lancet Oncol , 18 :312 –322 .
3.
Yamauchi
I
,
Sakane
Y
,
Fukuda
Y
,
Fujii
T
,
Taura
D
,
Hirata
M
,
Hirota
K
,
Ueda
Y
,
Kanai
Y
,
Yamashita
Y
,
Kondo
E
,
Sone
M
,
Yasoda
A
,
Inagaki
N
. 2017 . Clinical features of nivolumab-induced thyroiditis: a case series study . Thyroid , 27 :894 –901 .
4.
Guaraldi
F
,
La Selva
R
,
Samà
MT
,
D'Angelo
V
,
Gori
D
,
Fava
P
,
Fierro
MT
,
Savoia
P
,
Arvat
E
. 2018 . Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution . J Endocrin Invest , 41 :549 –556 .